Fresenius Medical Care (NYSE:FMS) Receives Lower Rating From DZ Bank. What’s The Reasoning Behind This Move?

October 18, 2018 - By Adrian Erickson

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Logo

Fresenius Medical Care (NYSE:FMS) Receives a Downgrade

Shares of Fresenius Medical Care (NYSE:FMS) were cut to a “Hold” by professional analysts at DZ Bank. FMS’s rating of a “Buy” has been discontinued.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Coverage

Among 2 analysts covering Fresenius Medical Care AG Common Stock (NYSE:FMS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fresenius Medical Care AG Common Stock had 2 analyst reports since April 24, 2018 according to SRatingsIntel. The stock of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has “Buy” rating given on Tuesday, August 28 by HSBC. The firm has “Buy” rating given on Tuesday, April 24 by Deutsche Bank.

The stock decreased 3.78% or $1.57 during the last trading session, reaching $39.91. About 530,042 shares traded or 260.46% up from the average. Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has risen 4.38% since October 18, 2017 and is uptrending. It has underperformed by 11.24% the S&P500.

Analysts await Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to report earnings on November, 1. They expect $0.67 EPS, up 13.56 % or $0.08 from last year’s $0.59 per share. FMS’s profit will be $408.08 million for 14.89 P/E if the $0.67 EPS becomes a reality. After $0.54 actual EPS reported by Fresenius Medical Care AG & Co. KGaA for the previous quarter, Wall Street now forecasts 24.07 % EPS growth.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. The company has market cap of $24.31 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure. It has a 10.67 P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

More notable recent Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) news were published by: Benzinga.com which released: “46 Biggest Movers From Yesterday” on October 18, 2018, also Benzinga.com with their article: “25 Stocks Moving In Thursday’s Pre-Market Session” published on October 18, 2018, 9News.com published: “This Denver company has spent the most money in the country opposing a ballot issue” on October 16, 2018. More interesting news about Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) were released by: Benzinga.com and their article: “31 Stocks Moving In Wednesday’s Pre-Market Session” published on October 17, 2018 as well as Seekingalpha.com‘s news article titled: “Fresenius down 18% premarket on softer earnings guidance” with publication date: October 17, 2018.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>